Joel Coste (Joël Coste)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 15

Top Topics

Polycystic Ovary Syndrome

Top Venues

European journal of public health

Therapeutic advances in musculoskeletal disease

Pharmacoepidemiology and drug safety

Journal of neurology

This page only lists publications with an associated author ORCID identifier.

Publications

Joel Coste, Jean-Marie Robine, Herman Van Oyen, Laure Carcaillon-Bentata
Metrological performances of the global chronic morbidity indicator of the Minimum European Health Module and implications for chronic disease prevalence and socioeconomic gradient estimations. European journal of public health 34 (4) (2024)
Joel Coste, Jean-Marie Robine, Herman Van Oyen, Laure Carcaillon-Bentata
Metrological performances of the global chronic morbidity indicator of the Minimum European Health Module and implications for chronic disease prevalence and socioeconomic gradient estimations. European journal of public health (2024)
Joel Coste, Jean-Marie Robine, Herman Van Oyen, Laure Carcaillon-Bentata
Metrological performances of the global chronic morbidity indicator of the Minimum European Health Module and implications for chronic disease prevalence and socioeconomic gradient estimations. European journal of public health 34 (4) (2024)
Sarah Tebeka, Laura Carcaillon-Bentata, Valentina Decio, Caroline Alleaume, Nathalie Beltzer, Anne Gallay, Cédric Lemogne, Baptiste Pignon, Tatjana T Makovski, Joel Coste
Complex association between post-COVID-19 condition and anxiety and depression symptoms. European psychiatry : the journal of the Association of European Psychiatrists (2023)
Joel Coste, Laurence Mandereau-Bruno, Laure Carcaillon-Bentata, Yann Mikaeloff, Viviane Bouilleret
Prevalence, demographic and spatial distribution of treated epilepsy in France in 2020: a study based on the French national health data system. Journal of neurology (2023)
Agnès Sola-Gazagnes, Catherine Pecquet, Stefano Berré, Peter Achenbach, Laure-Anne Pierson, Isabelle Virmoux-Buisson, Jocelyne M'Bemba, Fabienne Elgrably, Philippe Moguelet, Christian Boitard, Sophie Caillat-Zucman, Moussa Laanani, Joel Coste, Etienne Larger, Roberto Mallone
Insulin allergy: a diagnostic and therapeutic strategy based on a retrospective cohort and a case-control study. Diabetologia 65 (8) (2022)
Joel Coste, Terkia Medkour, Jean-Yves Maigne, Marc Pérez, Françoise Laroche, Serge Perrot
Response to Alvarez et al. Therapeutic advances in musculoskeletal disease 13 (2021)
Joel Coste, Terkia Medkour, Jean-Yves Maigne, Marc Pérez, Françoise Laroche, Serge Perrot
Osteopathic medicine for fibromyalgia: a sham-controlled randomized clinical trial. Therapeutic advances in musculoskeletal disease 13 (2021)
Alain Weill, Pierre Nguyen, Moujahed Labidi, Benjamin Cadier, Thibault Passeri, Lise Duranteau, Anne-Laure Bernat, Isabelle Yoldjian, Sylvie Fontanel, Sébastien Froelich, Joel Coste
Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. BMJ (Clinical research ed.) 372 (2021)
Benjamin Bouyer, Fanny Leroy, Jérémie Rudant, Alain Weill, Joel Coste
Burden of fractures in France: incidence and severity by age, gender, and site in 2016. International orthopaedics 44 (5) (2020)
Joel Coste, Xavier Bertagna, Mahmoud Zureik
Comment on: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?" Clinical pharmacokinetics 58 (7) (2020)
Joel Coste, Alexandre Karras, Annie Rudnichi, Rosemary Dray-Spira, Jacques Pouchot, Philippe Giral, Mahmoud Zureik
Statins for primary prevention of cardiovascular disease and the risk of acute kidney injury. Pharmacoepidemiology and drug safety 28 (12) (2019)
Amélie Poidvin, Jean-Claude Carel, Emmanuel Ecosse, Dominique Levy, Jean Michon, Joel Coste
Increased risk of bone tumors after growth hormone treatment in childhood: A population-based cohort study in France. Cancer medicine (2018)
Joel Coste
Diverging approaches of pharmacovigilance and pharmacoepidemiology to assessing drug safety: epistemological and ethical implications. Pharmacoepidemiology and drug safety 26 (5) (2017)
Françoise Laroche, Serge Perrot, Terkia Medkour, Paul-Henri Cottu, Jean-Yves Pierga, Jean-Pierre Lotz, Karine Beerblock, Christophe Tournigand, Laure Chauvenet, Didier Bouhassira, Joel Coste
Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study. PloS one 12 (11) (2017)